Tesamorelin Peptide: Dosage, Protocol, Reconstitution, and Fat Loss Guide
Tesamorelin Peptide
Tesamorelin is a synthetic GHRH analog that stimulates natural growth hormone release, increasing IGF-1 levels and promoting fat loss—particularly visceral fat. It is FDA-approved for HIV-associated lipodystrophy and widely studied for metabolic and body composition improvements.
How Tesamorelin Works
GHRH → Growth Hormone ↑ → IGF-1 ↑ → Lipolysis ↑ → Visceral Fat ↓
Tesamorelin stimulates the pituitary to release growth hormone in a natural pulsatile rhythm. This increases IGF-1, enhancing fat metabolism while preserving lean mass and avoiding suppression of endogenous GH production.
Tesamorelin is a GHRH analog, meaning it signals the pituitary to release growth hormone naturally.
It is best known for visceral fat reduction, especially in clinical HIV-associated lipodystrophy research and treatment settings.
It increases IGF-1 signaling while supporting fat metabolism and lean mass preservation.
Because it can affect glucose and fluid balance, monitoring is important during longer cycles.
Tesamorelin Protocol
10 mg vial + 3.0 mL BAC Water → 1 unit = 33.3 mcg → Visceral Fat + GH Support
Standard Setup
Vial
10 mg
Water
3.0 mL bacteriostatic water
Concentration
3.33 mg/mL
Conversion
1 unit = 33.3 mcg
Week 1
Start Phase
Dose1 mg (1000 mcg)
Units30 units
Volume0.30 mL
Weeks 2+
Full Dose
Dose2 mg (2000 mcg)
Units60 units
Volume0.60 mL
Protocol Details
FrequencyOnce daily
TimingEvening
Cycle Length12–26 weeks
Clinical DurationUp to 52 weeks in clinical settings
Simple structure
Tesamorelin is usually discussed as a longer metabolic and body-composition protocol. Short runs may not be enough to fully evaluate visceral fat changes, so tracking over time matters.
Tesamorelin is usually discussed as a longer metabolic and body-composition protocol. Short runs may not be enough to fully evaluate visceral fat changes, so tracking over time matters.
Dosing Notes
Start at 1 mg to assess tolerance
Increase to 2 mg for the full protocol target
Evening dosing may better align with natural GH rhythm
Longer cycles typically produce clearer fat-loss outcomes
Monitor glucose, fluid retention, and joint symptoms during longer use
How to Use Tesamorelin (Timing & Injection)
Injection TypeSubcutaneous
Common SiteAbdomen
TimingEvening, consistent time daily
Use StyleMetabolic / visceral fat protocol
When & Where to Inject
Inject subcutaneously in the abdomen
Avoid the area within 2 inches of the navel
Rotate injection sites daily
Inject at a consistent time each evening
Avoid irritated, bruised, scarred, or hardened areas
Timing Notes
Evening use is commonly discussed because GH release naturally rises during sleep.
Consistent daily timing helps make response and side effects easier to track.
Tesamorelin works best as part of a structured metabolic plan, not as a quick fat-loss shortcut.
Reconstitution & Dosing (10 mg Vial)
Vial10 mg
Water3.0 mL bacteriostatic
Concentration3.33 mg/mL
Conversion1 unit = 33.3 mcg
Dose Reference
30 units = 1 mg (1000 mcg)
60 units = 2 mg (2000 mcg)
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Ensure solution is clear
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C / 35–46°F
Long-term storage: freezing at −20°C / −4°F is commonly preferred
Estimated refrigerated shelf life: commonly ~12–24 months when sealed, dry, and protected from light
Estimated frozen shelf life: commonly up to ~2–3 years when stored properly
Keep sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Do not repeatedly freeze and thaw the same vial
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C / 36–46°F
Use within 7 days after reconstitution
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
Tesamorelin should be kept cold and protected from light. Once mixed, it has a shorter use window than many peptides, so label the vial with the mix date and use within the stated window.
Tesamorelin should be kept cold and protected from light. Once mixed, it has a shorter use window than many peptides, so label the vial with the mix date and use within the stated window.
Cycle Length & Time Between Cycles
Visceral Fat Phase → Monitor IGF-1 + Glucose → Reassess → Continue or Break
Standard Cycle Structure
Cycle Length12–26 weeks
Clinical DurationUp to 52 weeks
Primary GoalVisceral fat reduction + IGF-1 support
Use StyleLonger metabolic protocol
Time Between Cycles
Break4–8 weeks after longer cycles
Allows IGF-1, glucose, and fluid balance to be reassessed
Helps determine whether visceral fat changes are maintained
Gives time to evaluate whether continued therapy is still appropriate
Why cycle?
Tesamorelin is often studied over longer timeframes, but breaks and reassessment periods help evaluate IGF-1 response, glucose tolerance, fluid retention, and whether the body-composition goal is still active.
Tesamorelin is often studied over longer timeframes, but breaks and reassessment periods help evaluate IGF-1 response, glucose tolerance, fluid retention, and whether the body-composition goal is still active.
Monitoring During Use
IGF-1 levels, key biomarker
Body composition and visceral fat changes
Blood glucose and HbA1c
Lipid profile
Fluid retention or edema
Joint discomfort or carpal tunnel-like symptoms
Benefits
Reduces visceral abdominal fat
Increases natural growth hormone levels
Improves IGF-1 signaling
Supports metabolic health
May support liver fat reduction in NAFLD-related discussions
Preserves lean muscle mass
Potential Side Effects
Injection site irritation
Water retention
Joint stiffness or discomfort
Mild increase in blood glucose
Carpal tunnel-like symptoms, rare
Possible IGF-1 elevation beyond target range if not monitored
Stacking Strategies
Visceral Fat Support → Metabolic Pairing → Monitor Glucose + IGF-1
Common Pairing Approaches
Fat Loss: Tesamorelin + GLP-1 (Tirzepatide / Semaglutide)
Advanced: Tesamorelin + Ipamorelin
Metabolic: Tesamorelin + NAD+
What to Avoid
Stacking multiple GH-pathway peptides without IGF-1 monitoring
Ignoring glucose changes when combining with metabolic compounds
Using without a nutrition, protein, and resistance-training plan
Simple rule
Tesamorelin is already a strong metabolic GH-pathway peptide. Stacking should focus on a clear goal, usually visceral fat, metabolic support, or body composition, while monitoring glucose and IGF-1 response.
Tesamorelin is already a strong metabolic GH-pathway peptide. Stacking should focus on a clear goal, usually visceral fat, metabolic support, or body composition, while monitoring glucose and IGF-1 response.
Important Notes
FDA-approved for HIV-associated lipodystrophy
Most associated with visceral fat reduction
Longer cycles produce clearer body-composition outcomes
Glucose and IGF-1 monitoring matter during use
Not the same as general weight-loss medication
Works best with structured nutrition and training support
Important Disclaimer
Tesamorelin is FDA-approved for specific medical use but should only be used under medical supervision. This content is for educational purposes only.
Comments
Post a Comment